Share
Market Research Report

LATAM FABRY DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Segmentation
  • By Therapy TypeEnzyme Replacement Therapy (Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Pegunigalsidase Alfa (PRX-102, Phase III)) Chaperon Therapy (Migalastat (Galafold Phase III)) · Substrate Reduction Therapy (Lucerastat (Phase III), Venglustat (Phase III))
  • By Route of AdministrationOral · Parenteral
  • By Distribution ChannelHospitals Pharmacies · Online pharmacies · Retail Pharmacies
  • By GeographyLatin America
  • Published In31 Mar 2026
  • Report CodeCMI5249
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026 - 2033

LATAM Fabry Disease Market Segmentation

  • By Therapy Type (Revenue, USD Mn, 2020 - 2033)

    • Enzyme Replacement Therapy
      • Agalsidase Beta (Fabrazyme)
      • Agalsidase Alfa (Replagal)
      • Pegunigalsidase Alfa (PRX-102, Phase III)
    • Chaperon Therapy
      • Migalastat (Galafold Phase III)
    • Substrate Reduction Therapy
      • Lucerastat (Phase III)
      • Venglustat (Phase III)

  • By Route of Administration Insights (Revenue, USD Mn, 2020 - 2033)

    • Oral
    • Parental

  • By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)

    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online pharmacies

  • By Country Insights (Revenue, USD Mn, 2020 - 2033)

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America